Autori: Zamagni Elena
| Naslov | Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial (Meeting Abstract) |
| Autori | Zamagni Elena ... Bila Jelena S ... (broj koautora 53) |
| Info | BLOOD, (2024), vol. 144 br. , Suppl. 1, str. 495-498 |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa |
| Naslov | MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab plus Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma (Meeting Abstract) |
| Autori | Zamagni Elena ... Bila Jelena S ... (broj koautora 22) |
| Info | BLOOD, (2022), vol. 140 br. , Suppl. 1, str. 7289-7291 |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa |
